We've found
12,064 Hematology
clinical trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Bacteremia Clinical Trial
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Bacteremia Clinical Trial
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Anemia, Hemolytic, Autoimmune Clinical Trial
A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
Status: Enrolling,
Phase
I
Updated: 3/13/2018
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neoplasms Clinical Trial
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neoplasms Clinical Trial
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
AML, Adult Clinical Trial
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
Status: Enrolling,
Phase
Updated: 3/9/2018
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
12,064 Hematology
clinical trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Bacteremia Clinical Trial
Updated: 12/31/1969
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Bacteremia Clinical Trial
Updated: 12/31/1969
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
Updated: 12/31/1969
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
Updated: 12/31/1969
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Updated: 12/31/1969
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Updated: 12/31/1969
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Updated: 12/31/1969
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Anemia, Hemolytic, Autoimmune Clinical Trial
Updated: 3/13/2018
A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
Status: Enrolling,
Phase
I
Updated: 3/13/2018
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neoplasms Clinical Trial
Updated: 12/31/1969
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neoplasms Clinical Trial
Updated: 12/31/1969
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
AML, Adult Clinical Trial
Updated: 12/31/1969
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
Updated: 12/31/1969
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 3/9/2018
Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
Status: Enrolling,
Phase
Updated: 3/9/2018
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Updated: 12/31/1969
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials